UroGen’s Bladder Cancer Drug Draws Split Decision From US FDA Panel

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee voted 5-4 that the overall benefit-risk of UGN-102 is not favorable in patients with recurrent low grade, intermediate-risk, non-muscle invasive bladder cancer and also divided on whether randomized trials should be required for future development programs.

Dividing line
An FDA advisory committee was divided on UroGen's application for bladder cancer, as well as future approval standards. (Shutterstock)

More from US Advisory Committees

More from Pink Sheet